Citation Impact
Citing Papers
Sensitization of Human Carcinoma Cells to Alkylating Agents by Small Interfering RNA Suppression of 3-Alkyladenine-DNA Glycosylase
2005 StandoutNobel
Structure, Function, and Inhibition of O6-Alkylguanine-DNA Alkyltransferase
1995
Mismatch Repair-dependent Iterative Excision at Irreparable O6-Methylguanine Lesions in Human Nuclear Extracts
2006 StandoutNobel
ATP-Dependent Efflux of CPT-11 and SN-38 by the Multidrug Resistance Protein (MRP) and Its Inhibition by PAK-104P
1999
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
2008 StandoutNature
In vivo release from a drug delivery MEMS device
2004
IKKβ Links Inflammation and Tumorigenesis in a Mouse Model of Colitis-Associated Cancer
2004 Standout
EGFR Antagonists in Cancer Treatment
2008 Standout
Bioorthogonal Chemistry: Fishing for Selectivity in a Sea of Functionality
2009 StandoutNobel
Demethylation of 3-Methylthymine in DNA by Bacterial and Human DNA Dioxygenases
2004 StandoutNobel
Phase 1 trial of temozolomide plus irinotecan plus O6‐benzylguanine in adults with recurrent malignant glioma
2009
Phase I Trial of Single-Dose Temozolomide and Continuous Administration of O6-Benzylguanine in Children with Brain Tumors: a Pediatric Brain Tumor Consortium Report
2007
Integrins in cancer: biological implications and therapeutic opportunities
2009 Standout
Cisplatin: mode of cytotoxic action and molecular basis of resistance
2003 Standout
Phase 2 study of weekly irinotecan in adults with recurrent malignantglioma: Final report of NABTT 97-11
2004
Biodegradable nanoparticles for drug and gene delivery to cells and tissue
2003 Standout
Chitosan-based hydrogels for controlled, localized drug delivery
2009 Standout
Self-protecting core-shell magnetic nanoparticles for targeted, traceable, long half-life delivery of BCNU to gliomas
2011
The effectiveness of a magnetic nanoparticle-based delivery system for BCNU in the treatment of gliomas
2010
Inactivation of the DNA-Repair GeneMGMTand the Clinical Response of Gliomas to Alkylating Agents
2000 Standout
Conserved structural motifs governing the stoichiometric repair of alkylated DNA by O6-alkylguanine-DNA alkyltransferase
2000
Mismatch repair and nucleotide excision repair proteins cooperate in the recognition of DNA interstrand crosslinks
2009 StandoutNobel
Peptide dendrimers: applications and synthesis
2002
Network pharmacology: the next paradigm in drug discovery
2008 Standout
Recent progress on the Ada response for inducible repair of DNA alkylation damage
2002 StandoutNobel
Biodegradable polymer implants to treat brain tumors
2001
Stimuli-responsive nanocarriers for drug delivery
2013 Standout
Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer
2004 Standout
Stimulated Emission Depletion Nanoscopy of Living Cells Using SNAP-Tag Fusion Proteins
2010 StandoutNobel
Advances in Brain Tumor Surgery
2007
Molecular mechanisms of cisplatin resistance
2011 Standout
Active and alkylated human AGT structures: a novel zinc site, inhibitor and extrahelical base binding
2000
Phase I trial of O6-benzylguanine for patients undergoing surgery for malignant glioma.
1998
Minimal Methylated Substrate and Extended Substrate Range of Escherichia coli AlkB Protein, a 1-Methyladenine-DNA Dioxygenase
2003 StandoutNobel
Targeting multidrug resistance in cancer
2006 Standout
Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma
2005
Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials
1997
Cellular processing of platinum anticancer drugs
2005 Standout
A general method for the covalent labeling of fusion proteins with small molecules in vivo
2002 Standout
The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage
1999 StandoutNatureNobel
Targeted therapy for brain tumours
2004
Malignant Gliomas in Adults
2008 Standout
Mechanisms of drug combinations: interaction and network perspectives
2009 Standout
Quantification of O 6 -methylguanine-DNA methyltransferase mRNA in human brain tumors
1996
EFFECT OF THE ANGIOGENESIS INHIBITOR CILENGITIDE (EMD 121974) ON GLIOBLASTOMA GROWTH IN NUDE MICE
2006
DNA Repair: Enzymatic Mechanisms and Relevance to Drug Response
1996
Delayed repletion of O6-methylguanine—DNA methyltransferase resulting in failure to protect the human glioblastoma cell line SF767 from temozolomide-induced cytotoxicity
2003
Genotoxicity of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU)
1995
Current and future developments in the use of temozolomide for the treatment of brain tumours
2001
Tobacco Smoke Carcinogens and Lung Cancer
1999 Standout
Neuroblastoma
2007 Standout
Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma
2005 Standout
An error catastrophe in cancer?
2004
The role of human O6-alkylguanine-DNA alkyltransferase in promoting 1,2-dibromoethane-induced genotoxicity in Escherichia coli
2000
Strategies for optimizing combinations of molecularly targeted anticancer agents
2006
The anti-angiogenic basis of metronomic chemotherapy
2004 Standout
Designing dendrimers for biological applications
2005 Standout
Repair of O6-alkylguanine by alkyltransferases
2000
Cancer as an evolutionary and ecological process
2006 Standout
Characterisation of a human small-cell lung cancer cell line resistant to the DNA topoisomerase I-directed drug topotecan
1995
Topoisomerase I inhibitors: camptothecins and beyond
2006 Standout
Diagnosis and Treatment of High-Grade Astrocytoma
2007
MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
2005 Standout
Brain tumor cell lines resistant to O6-benzylguanine/1,3-bis(2-chloroethyl)-1-nitrosourea chemotherapy have O6-alkylguanine-DNA alkyltransferase mutations
2004 StandoutNobel
Biochemical Modulation of Cisplatin Mechanisms of Action: Enhancement of Antitumor Activity and Circumvention of Drug Resistance
2003 Standout
Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview
2012 Standout
Mechanism of polyoxometalate-mediated inactivation of DNA polymerases: an analysis with HIV-1 reverse transcriptase indicates specificity for the DNA-binding cleft
1996
Changes in topoisomerase I levels and localization during myeloid maturation in vitro and in vivo.
1995
Mismatch Repair Deficiency Does Not Mediate Clinical Resistance to Temozolomide in Malignant Glioma
2008 StandoutNobel
Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair–deficient malignant glioma xenograft
2005 StandoutNobel
Degradable Controlled-Release Polymers and Polymeric Nanoparticles: Mechanisms of Controlling Drug Release
2016 Standout
Phase I Trial of Temozolomide and Protracted Irinotecan in Pediatric Patients with Refractory Solid Tumors
2004
Phase II Trial of Temozolomide Plus O6-Benzylguanine in Adults With Recurrent, Temozolomide-Resistant Malignant Glioma
2009
The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux.
2001
3-aminobenzamide and/or O6-benzylguanine evaluated as an adjuvant to temozolomide or BCNU treatment in cell lines of variable mismatch repair status and O6-alkylguanine-DNA alkyltransferase activity
1996
The antitumour activity of alkylating agents is not correlated with the levels of glutathione, glutathione transferase and O6-alkylguanine-DNA-alkyltransferase of human tumour xenografts
1998
Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma
2008 Standout
O6-methylguanine-DNA methyltransferase-deficient phenotype in human gliomas: frequency and time to tumor progression after alkylating agent-based chemotherapy.
1999
Polyoxometalates in Medicine
1998 Standout
Msh2 status modulates both apoptosis and mutation frequency in the murine small intestine
1999
Chemotherapy-induced O(6)-benzylguanine-resistant alkyltransferase mutations in mismatch-deficient colon cancer.
2002
Methylation-related chromatin structure is associated with exclusion of transcription factors from and suppressed expression of the O-6-methylguanine DNA methyltransferase gene in human glioma cell lines.
1994
Role of polymorphisms in codons 143 and 160 of the O6-alkylguanine DNA alkyltransferase gene in lung cancer risk
2000
Quantitative analysis of O6-alkylguanine-DNA alkyltransferase in malignant glioma
2006
Defective processing of methylated single-stranded DNA by E. coli alkB mutants
2000 StandoutNobel
Cross-resistance to camptothecin analogues in a mitoxantrone-resistant human breast carcinoma cell line is not due to DNA topoisomerase I alterations.
1995
Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer
1999 Standout
Blockage of abasic site repair enhances antitumor efficacy of 1,3-bis-(2-chloroethyl)-1-nitrosourea in colon tumor xenografts.
2003
Bevacizumab Plus Irinotecan in Recurrent Glioblastoma Multiforme
2007 Standout
Dendrimers Designed for Functions: From Physical, Photophysical, and Supramolecular Properties to Applications in Sensing, Catalysis, Molecular Electronics, Photonics, and Nanomedicine
2010 Standout
Circadian control of XPA and excision repair of cisplatin-DNA damage by cryptochrome and HERC2 ubiquitin ligase
2010 StandoutNobel
Targeted Disruption of the Mouse Topoisomerase I Gene by Camptothecin Selection
1996 StandoutNobel
Phase II Trial of Carmustine Plus O6-Benzylguanine for Patients With Nitrosourea-Resistant Recurrent or Progressive Malignant Glioma
2002
A reversible molecular valve
2005 StandoutNobel
Molecular Mechanisms of Mammalian DNA Repair and the DNA Damage Checkpoints
2004 StandoutNobel
Improvement of chemotherapy efficacy by inactivation of a DNA-repair pathway
2003
Works of M E Dolan being referenced
Extended depletion of O6-methylguanine-DNA methyltransferase activity following O6-benzyl-2'-deoxyguanosine or O6-benzylguanine combined with streptozotocin treatment enhances 1,3-bis(2-chloroethyl)-1-nitrosourea cytotoxicity.
1994
Effect of O6-benzylguanine on the sensitivity of human colon tumor xenografts to 1,3-BIS(2-chloroethyl)-1-nitrosourea(BCNU)
1993
Production of antibodies to peptide sequences present in human O6-alkylguanine-DNA alkyltransferase and their use to detect this protein in cell extracts
1991
Increased killing of prostate, breast, colon, and lung tumor cells by the combination of inactivators of O6-alkylguanine-DNA alkyltransferase and N,N′-bis(2-chloroethyl)-N-nitrosourea
1995
O6-benzylguanine potentiates the antitumor effect of locally delivered carmustine against an intracranial rat glioma.
2000
Effect of O6-benzylguanine on the sensitivity of human tumor xenografts to 1,3-bis(2-chloroethyl)-1-nitrosourea and on DNA interstrand cross-link formation.
1992
Elevated DNA polymerase alpha, DNA polymerase beta, and DNA topoisomerase II in a melphalan-resistant rhabdomyosarcoma xenograft that is cross-resistant to nitrosoureas and topotecan.
1994
Activity of temozolomide in the treatment of central nervous system tumor xenografts.
1995
Schedule-dependent activity of temozolomide plus CPT-11 against a human central nervous system tumor-derived xenograft.
2000 Nobel